GlassScriptPhysician profile
Shelley C Glover
NPI 1114969839
$2,204.00
in general payments reported to CMS, 2019-2025
27 companies · $564 in 2025
The $564 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $82.94 · 2021: $265 · 2022: $259 · 2023: $361 · 2024: $247 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,171.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $613.81 | 2021-2025 | Tisseel |
| Abbvie INC. | $436.39 | 2019-2025 | |
| Therapeuticsmd, INC. | $135.74 | 2019 | |
| Myovant Sciences INC. | $134.62 | 2021-2022 | |
| Exact Sciences Corporation | $119.08 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boston Scientific Corporation | $90.48 | 2023 | Advantage System |
| Pfizer INC. | $86.95 | 2023-2024 | |
| Revance Therapeutics, INC. | $83.33 | 2025 | Daxxify |
| Sumitomo Pharma America, INC. | $82.85 | 2023-2025 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $69.02 | 2025 | |
| Mayne Pharma Commercial LLC | $57.28 | 2025 | |
| Millicent US INC | $41.36 | 2020-2022 | |
| Organon LLC | $26.94 | 2025 | Nexplanon |
| Shield Therapeutics INC | $26.60 | 2025 | |
| Roche Diagnostics Corporation | $24.39 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $21.07 | 2019 | |
| Galderma Laboratories, L.P. | $19.72 | 2021 | |
| Merck Sharp & Dohme LLC | $18.92 | 2021 | |
| Coopersurgical, INC. | $18.24 | 2024 | Paragard T 380a |
| Astellas Pharma US INC | $17.72 | 2023 | Veozah |
| Medline Industries LP | $15.26 | 2025 | |
| Vertical Pharmaceuticals, LLC | $13.97 | 2019 | |
| Medtronic, INC. | $13.86 | 2025 | Truclear |
| Ferring Pharmaceuticals INC. | $13.29 | 2019 | |
| Allotrope Medical, INC | $12.44 | 2023 | Stimsite |
| Aspira Women'S Health INC | $10.67 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shelley Glover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.